Semaglutide is the newest GLP-1R agonist and
was approved by the FDA as a once-weekly injection for the treatment of
T2DM in late 2017. The peptide is chemically similar to liraglutide,
with the inclusion of two structural modifications (Lau, Bloch, et al., 2015).
The first is the replacement of Gly with the non-proteinogenic amino
acid 2-aminoisobutyric acid (Aib) at position 2. The second is the
attachment of octadecanoic diacid to the side chain of Lys-26 through a
short polyethylene glycol (PEG) spacer and a γ-glutamic acid linker.
The amino acid substitution renders the peptide more resistant to DPP-4
compared to liraglutide, and the presence of the 18-carbon fatty acid
moiety results in a high binding affinity for serum albumin, which
translates to a half-life of approximately 7 days in humans
Products Name: Semaglutide
CAS No.: 910463-68-2
Purity: >99.0%
Molecular Formula: C187H291N45O59
Molecular Weight: 4113.64g/mol
Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18diacid-γ-Glu-OEG-OEG)]-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
Appearance: White Lyophilized powder